Andrx lovastatin XL “approvable”
Executive Summary
Andrx' extended-release lovastatin Altocor (formally Avicor) receives "approvable" letter for treatment of hyperlipidemia. The NDA was filed March 29 (1"The Pink Sheet" April 2, 2001, p. 15)...
You may also be interested in...
Andrx Puts Branded Rx Line In Fast Lane: Ex-Bristol Exec Joins As CEO
Andrx CEO Richard Lane will oversee the launch of the extended-release lovastatin formulation Altocor
Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force
Andrx plans to launch extended-release lovastatin in 2002 for hyperlipidemia with three years of exclusivity, President Elliot Hahn, PhD, announced March 28 at the Banc of America Securities Healthcare Conference in Las Vegas.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.